Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder

   
   

The invention provides a method for assessing risk of a neurodegenerative disease or disorder in a subject. The method comprises comparing a level of anti-.beta.-amyloid-42 (A.beta..sub.42) antibody in a biological sample from a subject to a normal level, wherein a lower level in the biological sample from the subject indicates the risk of the disease or disorder. In a specific embodiment, the disease or disorder is Alzheimer's Disease (AD).

 
Web www.patentalert.com

< Gamma-secretase inhibitors

< Extended tethering approach for rapid identification of ligands

> Alzheimer's disease secretase, APP substrates therefor, and uses therefor

> Pyridazinone inhibitors of fatty acid binding protein and method

~ 00142